|
|
|
|
Small Stocks, Big Money™
|
|
Weekly Newsletter
|
|
|
|
|
|
|
|
Enlivex Reports Positive Phase IIa Results for Allocetra™ in Knee Osteoarthritis Trial
Enlivex (Nasdaq: ENLV) released encouraging 3-month topline data from its multi-country Phase I/II trial evaluating Allocetra™ in moderate-to-severe knee osteoarthritis. In the primary osteoarthritis subgroup, representing over half of the $7B+ global KOA market, Allocetra delivered a 72% reduction in pain and a 109% improvement in function vs. placebo, with statistically significant results across all key Phase III endpoints. The therapy maintained a favorable safety profile, with no related serious adverse events reported. Given the unmet need and projected market growth to $15.7B by 2030, Enlivex sees Allocetra as a compelling future treatment option.
|
|
|
|
Trinity Biotech Secures Regulatory Greenlight for Outsourced HIV Test Manufacturing, Accelerating Strategic Shift
Trinity Biotech (Nasdaq: TRIB) has received critical regulatory approval to launch offshore and outsourced manufacturing of its high-volume, WHO-prequalified TrinScreen™ HIV rapid test. This move marks a key milestone in Trinity’s transformation strategy, unlocking immediate production under the new model while targeting gross margin expansion, reduced fixed costs, and enhanced scalability. The transition is expected to free up working capital and fuel long-term profitability as Trinity pivots toward a leaner, more growth-focused operating structure.
|
|
|
|
|
Atossa Taps PSI to Launch Pivotal Phase 2 Study of (Z)-Endoxifen in Metastatic Breast Cancer
Atossa Therapeutics (Nasdaq: ATOS) has selected global CRO PSI to lead its pivotal FDA-guided Phase 2 dose-ranging study of (Z)-endoxifen monotherapy in metastatic breast cancer. Designed to directly inform a registrational Phase 3 trial, the IND is expected in Q4 2025, with topline results anticipated in 2026. With a differentiated mechanism targeting resistant tumors and a strong safety profile in over 700 subjects, (Z)-endoxifen positions Atossa to compete in a multi-billion-dollar market with significant unmet need.
|
|
|
|
|
|
|
Greenwich LifeSciences Brings Clinical Ops In-House to Streamline Phase III Breast Cancer Trial
Greenwich LifeSciences (Nasdaq: GLSI) is building out an internal clinical operations team to directly manage its Phase III FLAMINGO-01 trial evaluating GLSI-100 for HER2+ breast cancer recurrence prevention. The shift aims to cut costs, improve trial efficiency, and boost data quality, while reducing reliance on external CROs. The move also sets the stage for Greenwich to run multiple studies in parallel, expanding GLSI-100 to new populations and supporting future in-licensed candidates.
|
|
|
|
|
FibroBiologics CEO Pete O’Heeron Champions Fibroblasts as the Future of Longevity Medicine
FibroBiologics (Nasdaq: FBLG) CEO Pete O’Heeron lays out a compelling case for fibroblasts as the next great leap in human health in a new editorial on the Opinion Pages. Arguing that these underappreciated cells outperform stem cells in tissue regeneration and chronic disease treatment, O’Heeron reveals how FibroBiologics has used fibroblasts to engineer a functional thymus organoid that reboots immune function and slows aging. Far beyond theory, this platform technology could redefine not just lifespan, but healthspan, marking a transformative frontier in regenerative medicine.
|
|
|
Recent News
|
|
|
Unlock Smarter Investing with RedChat
Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market.
Access RedChat now, free of charge.
|
|
|
|
Recent Research Coverage Updates
| Company |
Rating |
Price Target |
Firm |
Report Date |
| Greenwich LifeSciences (Nasdaq: GLSI) |
Buy |
$45 |
Noble |
August 20, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$7 |
HC Waingwright |
August 12, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Maxim |
August 12, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Maxim |
August 12, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 29, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7.5 |
Northland Securities |
July 23, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$4 |
Titan Partners |
July 17, 2025 |
| NioCorp (Nasdaq: NB) |
Buy |
$5 |
Maxim |
July 10, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7 |
H.C. Wainwright |
July 9, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 9, 2025 |
| NioCorp (Nasdaq: NB) |
Buy |
$4 |
HC Wainwright |
July 2, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$10 |
Maxim |
July 1, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$25 |
Lake Street |
June 17, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Craig Hallum |
June 5, 2025 |
| Creative Medical (Nasdaq: CELZ) |
Buy |
$8 |
Roth |
June 4, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$8 |
ThinkEquity |
June 2, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$7.25 |
Ascendiant Capital |
April 20, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$7 |
H.C. Wainwright |
March 24, 2025 |
| BioVie (Nasdaq: BIVI) |
Buy |
$6 |
Brookline |
March 18, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$15 |
ThinkEquity |
March 17, 2025 |
| Jupiter Neurosciences (Nasdaq: JUNS) |
Buy |
$30 |
Greenridge Global |
March 6, 2025 |
| Fathom Holdings (NASDAQ: FTHM) |
Buy |
$3.75 |
Roth |
March 3, 2025 |
| XORTX Therapeutics (Nasdaq: XRTX) |
Buy |
$14 |
AGP |
February 25, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$13 |
D. Boral |
February 7, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$18 |
Northland Capital Markets |
January 22, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$3 |
ThinkEquity |
January 13, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$27 |
Alliance Global Partners |
January 2, 2025 |
|
|
|
|
|
Small Stocks, Big Money™ Podcast
The podcast features in-depth interviews with CEO’s from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
Available on:
|
|
|
|
Upcoming Events
|
|
|
NASDAQ: LTRN - Lantern Pharma
4:15pm Eastern
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence.
|
|
|
|
NASDAQ: ASPI - ASP Isotopes
4:15pm Eastern
This exclusive event will provide investors with an opportunity to gain critical insights into ASP Isotopes' strategic initiatives and technological advancements.
|
|
|
|
Archived Events
|
|
|
NASDAQ: ENLV - Enlivex Therapeutics
8:00am Eastern
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses.
|
|
|
|
NASDAQ: NVA - Nova Minerals Limited
4:15pm Eastern
Nova Minerals Limited is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project, comprised of 513 km2 of State of Alaska mining claims, which contains multiple mining complexes across a 35 km long mineralized corridor of over 20 advanced Gold and Antimony prospects, including two already defined multi-million ounce resources, and several drill ready Antimony prospects with massive outcropping stibnite vein systems observed at surface.
|
|
|
|
Quote of the Week
|
" There is no passion to be found playing small - in settling for a life that is less than the one you are capable of living."
|
|
|
|
|
RedChip TV
|
|
|
|
RedChip Highlights Nova Minerals Limited (NASDAQ: NVA)
|
|
|
|
|
|
|
Order "Small Stocks, Big Money™ Today!
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
|
|
|
|
|
|
|
Lesson of the Week
Map your course for success with small-caps.
|
|
|
|
|
|
|
